Gesynta Pharma Logo


Gesynta Pharma's research on targeting mPGES-1, an essential enzyme in inflammation, began at Karolinska Institutet in Sweden. Gesynta Pharma’s shareholders include Hadean Ventures, Industrifonden, Innovestor Life Science, Linc, HealthCap, XGen Venture, and other internationally renowned specialist investors.
Gesynta Pharma

Low resolution

Medium resolution

Original resolution

About Us

Gesynta Pharma is a clinical-stage pharmaceutical company developing innovative treatments by targeting mPGES-1*, an important pro-inflammatory enzyme with a key role in endometriosis. Gesynta Pharma's research originated at Karolinska Institutet in Sweden. The company's leading compound, vipoglanstat, is a selective mPGES-1* inhibitor being developed as a new non-hormonal, non-opioid treatment with disease-modifying potential. Vipoglanstat is currently in Phase 2 clinical trials for endometriosis - a painful, chronic inflammatory disorder affecting about 10% of women of reproductive age. The condition often leads to a markedly reduced quality of life, particularly as many existing treatments fail to provide adequate symptom relief. Vipoglanstat has shown potent mPGES-1 inhibition and a favorable safety profile across Phase 1 and 2 clinical trials. Furthermore, a preclinical proof-of-concept study in an advanced model of endometriosis demonstrated that vipoglanstat significantly reduced pain-related behaviors and endometriotic lesions. A second drug candidate in the Gesynta Pharma portfolio, GS-073, is ready to enter clinical Phase 1 for the treatment of chronic inflammatory pain. The company's shareholders include Hadean Ventures, Industrifonden, Innovestor Life Science, Linc, HealthCap, XGen Venture, and other internationally renowned specialist investors. For more information, please visit www.gesynta.se. *mPGES-1: microsomal Prostaglandin E Synthase-1

Subscribe